Drug Trial Radar · NCT07288177
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Jan 30, 2026
Primary completion
Nov 22, 2027
Study completion Nov 22, 2028
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo. The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of cycle is 3 weeks). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
Rina-SDrug
Intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by InvestigatorTime frame: Approximately 3 years
Locations
102 sites in 14 countries. Site status is shown where the registry gives one.
Compassionate Cancer Care Center
Fountain Valley, California · Recruiting
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California · Recruiting
Kaiser Permanente San Diego Mission Road
San Diego, California · Recruiting
Providence Medical Foundation (St. Joseph Heritage Healthcare)
Santa Rosa, California · Recruiting
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Recruiting
University of Miami Hospital
Miami, Florida · Recruiting
Moffitt Cancer Center and Research Institute
Tampa, Florida · Recruiting
Emory Winship Cancer Institute
Atlanta, Georgia · Recruiting
St. Vincent Frontier Cancer Center
Billings, Montana · Recruiting
Nebraska Hematology-Oncology
Lincoln, Nebraska · Recruiting
Astera Cancer Care
East Brunswick, New Jersey · Recruiting
ONE Onc: New York Oncology Hematology
Albany, New York · Recruiting
Montefiore Medical Park
The Bronx, New York · Recruiting
UNC Health - University of North Carolina
Chapel Hill, North Carolina · Recruiting
Williamette Valley Cancer Institute and Research Center
Eugene, Oregon · Recruiting
Providence Portland Medical Center
Portland, Oregon · Recruiting
Providence Oncology & Hematology Care Clinic - Westside
West Haven-Sylvan, Oregon · Recruiting
Tennessee Oncology - Nashville St. Thomas Midtown Clinic
Nashville, Tennessee · Recruiting
Tennessee Oncology Nashville - SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Baylor Charles A. Sammons Cancer Center
Dallas, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
St Andrews Medical Centre
Adelaide, Australia · Recruiting
Blacktown Hospital
Blacktown, Australia · Recruiting
Chris O'Brien Lifehouse
Camperdown, Australia · Recruiting
St Vincent's Hospital - Melbourne
Fitzroy, Australia · Recruiting
Icon Cancer Centre Hobart
Hobart, Australia · Recruiting
Icon Cancer Care - Townsville
Hyde Park, Australia · Recruiting
Icon Cancer Centre Townsville ICON Cancer Care - Townsville
Hyde Park, Australia · Recruiting
St George Hospital
Kogarah, Australia · Recruiting
St John of God Murdoch Hospital
Murdoch, Australia · Recruiting
Sir Charles Gairdner Hospital
Nedlands, Australia · Recruiting
GenesisCare North Shore
Saint Leonards, Australia · Recruiting
Universitair Ziekenhuis Antwerpen
Edegem, Belgium · Recruiting
Jessa Ziekenhuis - Campus Virga Jesse
Hasselt, Belgium · Recruiting
Chu Helora Hospital La Louvière Site Jolimont
La Louvière, Belgium · Recruiting
UZ Leuven - Gasthuisberg Campus
Leuven, Belgium · Recruiting
AZ Delta (Campus Wilgenstraat)
Roeselare, Belgium · Recruiting
Beijing Cancer Hospital
Beijing, China · Recruiting
Beijing Chest Tumor Hospital
Beijing, China · Recruiting
Jilin Provincial Cancer Hospital
Changchun, China · Recruiting
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.